Antibiotice SA

As of June 30, 2026, Antibiotice SA carries a market capitalization of 1.45B, placing it among publicly traded companies globally. Its enterprise value stands at 1.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Antibiotice SA's next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, Antibiotice SA has 671.34M shares outstanding.

As of June 30, 2026, Antibiotice SA trades at a trailing price-to-earnings ratio of 178.68. The price-to-sales ratio is 2.38, and the price-to-book ratio stands at 1.56.

As of June 30, 2026, Antibiotice SA trades at an EV/EBITDA multiple of 21.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 67.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.80B versus a market cap of 1.45B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Antibiotice SA maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.60, indicating elevated leverage, while an interest coverage ratio of 16.27 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Antibiotice SA posted a return on equity (ROE) of 0.87, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.42 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.93, useful for judging operating efficiency across full business cycles. The company generates approximately 450,259.16 in revenue per employee across its workforce of 1,356.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.03 indicates how many times Antibiotice SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Antibiotice SA recorded 4.07M in income tax expense. That works out to an effective tax rate of 33.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.20M, leaving 8.13M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Antibiotice SA's stock has declined approximately 20.00% over the past 52 weeks. The 50-day moving average sits at 1.98, while the 200-day moving average is 2.07.

Over the twelve months ended June 30, 2026, Antibiotice SA generated 610.66M in revenue and converted that into 8.13M in net income, yielding earnings per share of 0.01. EBITDA reached 82.40M, while operating income came in at 21.52M.

As of June 30, 2026, Antibiotice SA holds 3.08M in cash and equivalents against 349.92M in total debt, resulting in a net debt position of 346.83M. Total book value stands at 930.75M, with working capital of 121.56M providing operational flexibility.

Antibiotice SA produced 88.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -181.46M in capital expenditures, free cash flow totaled -93.41M - equivalent to -0.14 per share.

Over the twelve months ended June 30, 2026, Antibiotice SA posted a gross margin of 63.26, reflecting its pricing power and cost economics. The operating margin of 3.52 and net profit margin of 1.33 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Antibiotice SA paid dividends of 0.02 per share. The dividend payout ratio of 146.72 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -6.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.56, meaning Antibiotice SA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Antibiotice SA's most recent stock split took place on July 11, 2013.

As of June 30, 2026, Antibiotice SA has an Altman Z-Score of 2.15, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.